Management Associate - Two Year Program (1 of 4)

Eligibility:
- Enrolled in, or recent graduate from, an advanced degree program (e.g., MBA, MS or MA)
- GPA of 3.5 or better (provide transcript or official letter of academic standing)

Why Novo Nordisk:

? Affiliates in 69 countries worldwide
? Named by Fortune Europe as one of the 10 best companies to work for
? Triple Bottom Line: not only focus on profit but also required to live up to social and environment responsibilities
? Over 80 years of innovation in diabetes management
? Research and innovation also in hemophilia and growth-hormone deficiency

Who We Are:

? Owned by Foundation of Scandinavian Scientists
? Consistent, strong financial performer
? Focused on a few Therapeutic Areas with unmet medical needs
? Global leader in Diabetes Care and Hemostasis Management
? Growing US platform
? Strong presence in Europe, Japan and emerging countries
? Proven biotech and drug delivery capabilities

Key Therapeutic Areas:

? Diabetes Care
? Hemostasis in Acute Care
? Human Growth Hormone
? HT (Hormone Therapy)

Why Management Associate at Novo Nordisk??

? Broad exposure to different aspects of the pharmaceutical business
? Leadership training
? Operational experience
? Potential for permanent placement at the end of the program
? Structured mentor relationship
? Work for a company that makes a difference

How to Be a Management Associate at Novo Nordisk

1: MAP Associate: Rotation program in four business units over two years. In order to be eligible for this position you must be a recent graduate from an advanced degree program.


Participating Business Units:
? Strategic Business Development
? Diabetes Sales
? Managed Care
? BioPharmaceuticals


Reqirements/Skills - ? Enrolled in, or recent graduate from, an advanced degree program (e.g., MBA, MS or MA)
? GPA of 3.5 or better (provide transcript or official letter of academic standing if selected
? Cover letter
? Resume
? Topic paper (1,000 words)

2006 Whitepaper Topic:
?If all drugs were pulled from the market based on the appearance of side effects, there would be no vaccinations for childhood diseases that once were killers, or for medications to treat HIV/AIDS.? In the wake of the controversy surrounding Cox-2 inhibitors, how do you think pharmaceutical companies could ensure a balance between maintaining profitability and promising strong safety profile?

Applicant will be contacted via email regarding additional submission information by MAP Representative





Apply online at http://nov.hrdpt.com